Literature DB >> 26584794

MEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity.

L Maubon1, N Hirji1, R Petrarca1, P Ursell1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26584794      PMCID： PMC4763129          DOI： 10.1038/eye.2015.243

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  4 in total

Review 1.  Clinical experience of MEK inhibitors in cancer therapy.

Authors:  Ding Wang; Scott A Boerner; James D Winkler; Patricia M LoRusso
Journal:  Biochim Biophys Acta       Date:  2006-11-16

Review 2.  MEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity.

Authors:  K E Duncan; L Y Chang; M Patronas
Journal:  Eye (Lond)       Date:  2015-06-05       Impact factor: 3.775

Review 3.  The clinical development of MEK inhibitors.

Authors:  Yujie Zhao; Alex A Adjei
Journal:  Nat Rev Clin Oncol       Date:  2014-05-20       Impact factor: 66.675

4.  First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.

Authors:  Maria Martinez-Garcia; Udai Banerji; Joan Albanell; Rastilav Bahleda; Saoirse Dolly; Françoise Kraeber-Bodéré; Federico Rojo; Emilie Routier; Ernesto Guarin; Zhi-Xin Xu; Ruediger Rueger; Jean J L Tessier; Eliezer Shochat; Steve Blotner; Valerie Meresse Naegelen; Jean-Charles Soria
Journal:  Clin Cancer Res       Date:  2012-07-03       Impact factor: 12.531
  4 in total
  3 in total

1.  Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences from Central Serous Chorioretinopathy.

Authors:  Jasmine H Francis; Larissa A Habib; David H Abramson; Lawrence A Yannuzzi; Murk Heinemann; Mrinal M Gounder; Rachel N Grisham; Michael A Postow; Alexander N Shoushtari; Ping Chi; Neil H Segal; Rona Yaeger; Alan L Ho; Paul B Chapman; Federica Catalanotti
Journal:  Ophthalmology       Date:  2017-07-12       Impact factor: 12.079

Review 2.  Optic Pathway Glioma in Type 1 Neurofibromatosis: Review of Its Pathogenesis, Diagnostic Assessment, and Treatment Recommendations.

Authors:  Matteo Cassina; Luisa Frizziero; Enrico Opocher; Raffaele Parrozzani; Ugo Sorrentino; Elisabetta Viscardi; Giacomo Miglionico; Edoardo Midena; Maurizio Clementi; Eva Trevisson
Journal:  Cancers (Basel)       Date:  2019-11-14       Impact factor: 6.639

3.  Left ventricular ejection fraction decrease related to BRAF and/or MEK inhibitors in metastatic melanoma patients: A retrospective analysis.

Authors:  Mathilde Berger; Mona Amini-Adlé; Delphine Maucort-Boulch; Philip Robinson; Luc Thomas; Stéphane Dalle; Pierre-Yves Courand
Journal:  Cancer Med       Date:  2020-02-14       Impact factor: 4.452
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.